pages:
-
A Phase I Study of Microtransplantation in Combination with Nivolumab for Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Research Grant
-
A Phase I Study of the Kappa Opiate Receptor Occupancy and Clinical Mu Opiate Receptor Effects Associated with Repeated Dosing of LY2456302 Trial
-
A Phase I Study of the Safety of AAV2/8 LSPhGAA in Late-onset Pompe Disease
-
A PHASE I STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF ORALLY ADMINISTERED APG-2575 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
-
A Phase I study to evaluate the saftey, phamocokinetics and pharmacodynamics of JNJ-42756493 a pan-fibroblat growth factor receptor.
-
A Phase I trial of pomalidomide for children with recurrent, progressive or refractory CNS tumors
-
A Phase I Trial of a Bcl-2 inhibitor and a MEK inhibitor for patients with relapsed indolent B-NHL
Research Grant
-
A Phase I Trial of a Single ProHema CB Product (Ex Vivo Modulated Human Cord Blood Cells) as Part of Single Cord Blood Unit Transplant after Busulfan/Cyclophosphamide/ATG Conditioning for Pediatric Patients with Inherited Metabolic Disorders
-
A Phase I Trial of Fostamatinib before Chronic Graft-vs.-Host Disease Development after Allogeneic Stem Cell Transplantation
-
A Phase I Trial of Incorporating Natural Killer (K-NK) cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy
-
A Phase I trial of PVSRIPO for Patients with Unresectable Melanoma
-
A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)
-
A Phase I, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms
-
A Phase I, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 as a single agent in relapsed or refractory hematological malignancies and in combgination with Daratumumab as a Salvage Regimen for Multiple Myeloma
-
A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults with Active Pemphigus
-
A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults with Active Pemphigus
-
A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study Of Cenobamate (YKP3089) In Pediatric Subjects With Partial Onset Seizures
-
A phase I/2 open label study of Nivolumab monotherapy or Nivolmab combined with Ipilmumab in subjects with advanced or metastatic solid tumors.
-
A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING
THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER
(INTRINSIC)
-
A Phase I/Ib, Multicenter, Open-Label, Dose-Escalation Study of FT-2102 as a Single agent and in Combination with Azacitidine in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
-
A phase I/Ib, open label study of LSZ102 single agent and LSZ102 in combination with eitherLEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719)
in patients with advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.
Research Grant
-
A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients
-
A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno- Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B
-
A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUS
-
A Phase I/II, Open-label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination with Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients with Advanced Cancer
-
A Phase I/II, open-label, multicentre, dose escalation study assessing the safety and tolerability of pEYS606 when administered by electrotransfer (ET) in the ciliary muscle of patients with non infectious posterior, intermediate or panuveitis.
Research Grant
-
A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors
-
A PHASE Ib DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATIONWITH ATEZOLIZUMAB, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LU
-
A Phase IB Dose-Escalation Study of TRC105 in combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma
-
A PHASE Ib STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH ADVANCED BRAFV600 WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI¿PD-1 THERAPY
Research Grant
pages: